IP Library › Patent Application 11614108
Patent Application
App. No. 11/614,108

USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/614,108
Abstract

This invention provides a method of reducing mortality and morbidity after myocardial infarction. GLP-1, a GLP-1 analog, or a GLP-1 derivative, is administered at a dose effective to normalize blood glucose.

Claims (20)

1 - 12 . (canceled)

13 . A method for preventing or ameliorating injury to the myocardium following a myocardial infarction wherein an initial injury to the myocardium has occurred due to the myocardial infarction comprising administering to an individual an effective amount of a composition comprising GLP-1, a GLP-1 analog, or a GLP-1 derivative in a pharmaceutical carrier.

14 . The method of claim 13 wherein the injury to the myocardium is caused by free fatty acid oxidation.

15 . The method of claim 13 wherein the individual has hyperglycemia.

16 . The method of claim 13 wherein the individual has abnormal glucose tolerance.

17 . The method of claim 13 wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.

18 . A method of controlling the metabolic cascade that exacerbates infarct damage comprising administering GLP-1, a GLP-1 analog, or a GLP-1 derivative to a patient in need thereof.

19 . The method of claim 18 wherein the patient has suffered a myocardial infarction.

20 . The method of claim 19 wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.

21 . The method of claim 18 wherein the infarct damage occurs following a period of ischemia.

22 . The method of claim 18 wherein the patient has hyperglycemia.

23 . The method of claim 22 wherein the hyperglycemia is caused by a stress response to a myocardial infarction.

24 . The method of claim 18 wherein the patient has abnormal glucose tolerance.

25 . The method of claim 24 wherein the abnormal glucose tolerance is caused by a stress response to a myocardial infarction.

26 . A method for preventing or ameliorating damage to non-ischemic myocardium following a myocardial infarction comprising administering GLP-1, a GLP-1 analog, or GLP-1 derivative to a patient in need thereof.

27 . The method of claim 26 wherein the GLP-1, GLP-1 analog, or GLP-1 derivative is administered during the acute phase of a myocardial infarction.

28 . The method of claim 26 wherein the patient has hyperglycemia.

29 . The method of claim 28 wherein the hyperglycemia is caused by a stress response to a myocardial infarction.

30 . The method of claim 26 wherein the patient has abnormal glucose tolerance.

31 . The method of claim 30 wherein the abnormal glucose tolerance is caused by a stress response to a myocardial infarction.